TB-500: What the Research Actually Shows

TB-500 is a synthetic peptide tied to Thymosin Beta-4 (written Tbeta-4), a small protein found in nearly every cell in the body. Researchers have studied it mostly in one area: how cells move to close a wound and rebuild tissue after injury, in animal models and a few small human trials of Thymosin Beta-4 itself.

One thing to get straight up front. The published studies are on Thymosin Beta-4, the natural protein. TB-500 is the research-market name for a synthetic version of it, and we come back to that in the limits section.

What researchers have studied

Wound healing in rats (Journal of Investigative Dermatology, 1999). Researchers applied Thymosin Beta-4 to skin wounds in rats, on the surface and by injection. They observed new skin cover over the wound rise by 42 to 61 percent, with faster skin-cell migration. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/

Human venous ulcer trial (Annals of the New York Academy of Sciences, 2007). A European randomized study put topical Thymosin Beta-4 on venous leg ulcers in 72 patients over 84 days. It was mainly a safety and tolerability study, and researchers reported a signal toward faster healing at certain doses. One of the few human data points. PMID 17495250. https://pubmed.ncbi.nlm.nih.gov/17495250/

Blood vessel growth review (Angiogenesis, 2007). This paper reviewed how Thymosin Beta-4 affects new blood vessel growth and its possible role in heart and tissue repair. It lays out proposed mechanisms rather than running one experiment. PMID 17632766. https://pubmed.ncbi.nlm.nih.gov/17632766/

Skin-healing review (Vitamins and Hormones, 2016). A review summarized the dermal research. It noted Thymosin Beta-4 sped repair in Phase 2 trials of patients with pressure ulcers, stasis ulcers, and a blistering skin condition, along with positive results in animal models. PMID 27450738. https://pubmed.ncbi.nlm.nih.gov/27450738/

Eye-surface Phase 2 trials (ReGenTree, LLC). Two industry Phase 2 trials tested Thymosin Beta-4 eye solutions. One looked at corneal wounds in diabetic patients after eye surgery and was ended early for slow enrollment. The other looked at dry eye and was completed. Together they show the compound reached formal human testing for eye-surface repair. NCT00598871. https://clinicaltrials.gov/study/NCT00598871 and NCT01387347. https://clinicaltrials.gov/study/NCT01387347

How it works

Thymosin Beta-4’s main known job is binding actin, the protein cells use to build their inner skeleton and to move. When tissue is hurt, cells that rebuild skin and line blood vessels have to crawl toward the wound. Research suggests Thymosin Beta-4 helps organize actin so those cells migrate, which is a required first step for closing a wound and growing new vessels. TB-500 is studied as a synthetic stand-in for that activity.

What the research does not establish

• Most of the human-level evidence is on Thymosin Beta-4, the natural protein, not on the research-labeled “TB-500” by that name. That distinction matters.
• The strongest data is still early. Human trials are small, some sources are reviews, and at least one trial was ended before it finished.
• There is no approved human use. It is not an FDA-approved drug, and it has not been shown to be effective or safe for general use.
• Each finding describes a research model or a specific patient trial. It does not tell you what would happen in a healthy person.
• Nothing here is a safety conclusion, and this is not a claim that the compound is safe to use.

We would rather show you the gaps than paper over them. That is how you trust the parts that are solid.

For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Independent identity and purity testing by Janoshik. Nothing on this page is medical advice, a health claim, or a recommendation to use.